Influenza A and B conserved internal proteins (NP, M1, PB1, PB2, PA)

Influenza A and B conserved internal proteins, including the nucleoprotein (NP), matrix protein 1 (M1), and polymerase subunits (PB1, PB2, PA), are essential for viral replication and assembly. Unlike the surface proteins hemagglutinin and neuraminidase, which mutate rapidly, these internal proteins are highly conserved across diverse influenza strains and subtypes. This conservation makes them primary targets for the development of universal influenza vaccines aimed at providing broad, multi-season protection. Peptide antigens derived from these proteins are specifically designed to elicit cross-reactive T-cell responses, particularly CD8+ cytotoxic T lymphocytes and CD4+ helper T cells. When used as vaccine antigens, these peptides stimulate the immune system to recognize and eliminate virus-infected cells, thereby limiting viral replication and reducing the severity of the disease. While they generally do not induce neutralizing antibodies that provide sterilizing immunity, they offer a robust defense against heterosubtypic strains, including those with pandemic potential. Therapeutic candidates like FLU-v and Multimeric-001 utilize these conserved epitopes to overcome the limitations of traditional strain-specific vaccines.

Other names

Conserved internal influenza antigensUniversal influenza vaccine targetsInternal viral proteinsInfluenza nucleoprotein and matrix proteinsConserved influenza peptide antigens

Induction of cross-reactive T-cell (CD4+ and CD8+) and B-cell immune responses against highly conserved internal viral epitopes to provide heterosubtypic protection and reduce disease severity.